First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

529 Reviews

Credit Rating - NOVO PHARMACEUTICALS LIMITED

ANALYSIS
Credit Risk Update: ACCOUNTS DUE FLAG: NOVO PHARMACEUTICALS LIMITED, 1110 Elliott Court Coventry Business Park, Herald Avenue, Coventry, West Midlands, CV5 6UB. The legal status is a Private Limited Company and the current status at the registry of companies is Dissolved. The last filed accounts are dated 31 January 2018. The company was incorporated on 9 December 2014.

The accounts next due date is 31 October 2019. There are no mortgages.

The above was based on public record information as at 24 February 2025 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: 09348316
Date Incorporated: 9 December 2014
Date Latest Accounts: 31 January 2018
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: NOVO PHARMA LIMITED
Registered Number: 09348316
Annual Return: 9 December 2015
Registered Office: 1110 Elliott Court Coventry Business Park, Herald Avenue, Coventry, West Midlands, CV5 6UB
SIC Code and Operations: 99999
SECURED CREDITORS
Number of Mortgages 0
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 0
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

NOVO PHARMACEUTICALS LIMITED

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 6 March 2025 Copyright © 2025 First Report Ltd


Recent Searches

Reg No. Reg Name Status
08461856 NOVO PHYSIOTHERAPY LTD Active
08153339 NOVO PILATES LIMITED Active
OC432382 NOVO PLANNING LLP Active
15383504 NOVO PLUMBING LTD Active
14147169 NOVO PORTFOLIO SERVICES LIMITED Active

In using this service you agree to the Terms and Conditions

© 2025 First Report Ltd